Mesopram

Pricing Availability Delivery Time Qty
Cat.No. 3053 - Mesopram | C14H19NO4 | CAS No. 189940-24-7
Description: Orally active PDE4 inhibitor
Chemical Name: (R)-5-(4-Methoxy-3-propoxyphenyl)-5-methyl-2-oxazolidinone
Purity: ≥98% (HPLC)
Datasheet
Citations
Literature

Biological Activity

Orally active phosphodiesterase (PDE) 4 inhibitor. Inhibits Th1 cell proliferation and decreases production of IFN-γ, TNF-α, IL-10 and iNOS in vitro. Triggers ovulation and exhibits efficacy against experimental autoimmune encephalomyelitis and murine colitis in vivo.

Technical Data

M. Wt 265.31
Formula C14H19NO4
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 189940-24-7
PubChem ID 449190
InChI Key PCCPERGCFKIYIS-AWEZNQCLSA-N
Smiles O=C1O[C@@](C2=CC(OCCC)=C(OC)C=C2)(C)CN1

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

All Tocris products are intended for laboratory research use only.

Solubility Data

Solvent Max Conc. mg/mL Max Conc. mM
Solubility
DMSO 26.53 100
ethanol 26.53 100

Preparing Stock Solutions

The following data is based on the product molecular weight 265.31. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 3.77 mL 18.85 mL 37.69 mL
5 mM 0.75 mL 3.77 mL 7.54 mL
10 mM 0.38 mL 1.88 mL 3.77 mL
50 mM 0.08 mL 0.38 mL 0.75 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

Product Datasheets

Safety Datasheet

References

References are publications that support the products' biological activity.

Dinter et al (2000) The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J.Neuroimmunol. 108 136 PMID: 10900347

Loher et al (2003) The specific type-4 phosphodiesterase inhibitor mesopram alleviates experimental colitis in mice. J.Pharmacol.Exp.Ther. 305 549 PMID: 12606674

McKenna et al (2005) Pharmacological inhibition of phosphodiesterase 4 triggers ovulation in follicle-stimulating hormone-primed rats. Endocrinology 146 208 PMID: 15448112


If you know of a relevant reference for Mesopram, please let us know.

View Related Products by Target

View Related Products by Product Action

View all Phosphodiesterase Inhibitors

Keywords: Mesopram, supplier, Orally, active, PDE4, inhibitors, inhibits, Phosphodiesterases, Phosphodiesterases, Phosphodiesterases, Tocris Bioscience

Citations for Mesopram

Citations are publications that use Tocris products.

Currently there are no citations for Mesopram. Do you know of a great paper that uses Mesopram from Tocris? If so please let us know.

Mesopram Reviews

Average Rating:

(Based on 0 Reviews)


1 Star
0%
2 Star
0%
3 Star
0%
4 Star
0%
5 Star
0%

Have you used Mesopram?

Submit a review and receive a $25US/€18/£15/$25CAN Amazon gift card if you include an image -$10US/€7/£6/$10CAN Amazon gift card for reviews without an image. Limited to verified customers in USA, Canada and Europe.


Literature in this Area

Cardiovascular

Cardiovascular Research Product Guide

A collection of over 250 products for cardiovascular research, the guide includes research tools for the study of:

  • Hypertension
  • Thrombosis and Hemostasis
  • Atherosclerosis
  • Myocardial Infarction
  • Ischemia/Reperfusion Injury
  • Arrhythmias
  • Heart Failure
Asthma

Asthma Poster

Asthma is one of the most common chronic diseases in the world, affecting over 300 million people. This poster highlights key pathways and new therapies used to treat the condition, including those currently in clinical development.